Gene-Editing Biotech Prime Medicine Strikes Up Cell Therapy R&D Alliance With Bristol Myers Squibb
Prime Medicine, a biotech company that set out to use its more precise approach to gene editing to develop new one-time treatments for rare diseases, is expanding its scope to more prevalent therapeutic areas under a new partnership with Bristol Myers …